Facilitating Innovative Nuclear Diagnostics Act of 2023

H.R. 1199, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023, would change how Medicare pays for advanced medical imaging tests that use radioactive drugs, known as diagnostic radiopharmaceuticals. Currently, Medicare bundles the cost of these drugs into a single flat payment for the entire imaging procedure, which can sometimes be less than the cost of the drug itself. This bill would require Medicare to pay for high-cost radiopharmaceuticals separately from the procedure, ensuring that hospitals are fully reimbursed for using these specialized tools to detect conditions like Alzheimer’s, Parkinson’s, and certain cancers. For patients, this change is intended to increase access to more precise diagnostic technologies at local hospitals and reduce the likelihood of being referred to distant facilities for advanced scans.